Biotricity (Biotricity) EBIT : $-9.58 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biotricity EBIT?

Biotricity's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.58 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biotricity's annualized ROC % for the quarter that ended in Dec. 2023 was -40.31%. Biotricity's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -462.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biotricity's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -26.31%.

Biotricity EBIT Historical Data

The historical data trend for Biotricity's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity EBIT Chart

Biotricity Annual Data

Trend

Aug14

Aug15

Dec16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT

Get a 7-Day Free Trial

-8.59

-10.98

-13.01

-18.56

-16.08

Biotricity Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-4.05	-3.45	-2.20	-2.34	-1.60

Competitive Comparison of Biotricity's EBIT

For the Medical Devices subindustry, Biotricity's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotricity's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biotricity's EV-to-EBIT falls into.

Biotricity EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.58 Mil.

Biotricity (NAS:BTCY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biotricity's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-5.128 * ( 1 - 0% )	/	( (12.82	+	12.625)	/ 2 )
=	-5.128	/	12.7225
=	-40.31 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.824	-	6.65	-	( 1.2	-	max(0, 17.824	-	5.178	+	1.2	))
=	12.82

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.486	-	7.548	-	( 0.085	-	max(0, 18.619	-	3.932	+	0.085	))
=	12.625

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Biotricity's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.38	/	( ( (1.428 + max(-5.804, 0))	+	(1.333 + max(-4.864, 0)) )	/	2 )
=	-6.38	/	( ( 1.428	+	1.333 )	/	2 )
=	-6.38	/	1.3805
=	-462.15 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.61	+	2.128	+	0)	-	(6.65	+	0.009	+	2.883)
=	-5.804

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.574	+	2.049	+	0)	-	(7.548	+	0.011	+	0.928)
=	-4.864

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biotricity's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-9.578	/	36.410
	=	-26.31 %

Biotricity EBIT Related Terms

Thank you for viewing the detailed overview of Biotricity's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotricity (Biotricity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

QB00:Germany

Address

275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065

Website

https://www.biotricity.com

Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.

Executives

Chester P White	director	447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon	director	1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy	director	275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts	director	275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq	director, 10 percent owner, officer: CEO and Chairman of the Board	C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou	officer: Chief Financial Officer	C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065